Following a series of tragic incidents in late 2025, the Indian government has moved to strictly regulate the use of pediatric medications. The Directorate General of Health Services (DGHS) and the Union Health Ministry have issued a comprehensive advisory that effectively bans the administration of cough and cold syrups for children under the age of 2.
This decision is part of a broader crackdown on pharmaceutical safety after contaminated syrups were linked to child deaths in Madhya Pradesh and Rajasthan.
1. The Core Directive
The new guidelines, which are being strictly enforced as of April 2026, emphasize that most coughs in infants are self-limiting and do not require pharmacological intervention.
- Under 2 Years: Complete prohibition on the use of over-the-counter (OTC) cough and cold formulations.
- Under 5 Years: Discouraged use; pediatricians are advised to avoid prescribing these medications unless absolutely necessary and to favor natural remedies or hydration.
- Rational Use: The government is pushing for “rational use” of medicines, noting that many syrups contain ingredients like Dextromethorphan which are not recommended for pediatric use due to potential neurotoxicity.
2. The Catalyst: The 2025 Contamination Crisis
The ban is a direct response to a major public health alert that began in October 2025.
- The Incident: Over 20 children in Madhya Pradesh (Chhindwara district) and several in Rajasthan died from acute kidney failure after consuming a syrup branded as Coldrif.
- The Contaminant: Laboratory tests confirmed the presence of Diethylene Glycol (DEG) at levels as high as 48.6%—thousands of times higher than the permissible limit. DEG is an industrial solvent that is highly toxic to the kidneys and nervous system.
- Manufacturer Action: The manufacturer, Sresan Pharmaceuticals, had its license revoked, and its headquarters were raided by the Enforcement Directorate.
3. Regulatory Enforcement: The “Coldrif” Ban
While the advisory covers all pediatric syrups for infants, the government has placed specific bans on three toxic formulations identified during the 2025-2026 inspections:
| Toxic Syrup | Manufacturer | Status |
| Coldrif | Sresan Pharmaceuticals (TN) | Nationwide Ban; Manufacturer under criminal probe. |
| Respifresh TR | Rednex Pharmaceuticals (GJ) | Recalled due to DEG contamination. |
| RELIFE | Shape Pharma (GJ) | Recalled due to DEG contamination. |
4. New Safety Protocols for FY27
To restore trust in the “Pharmacy of the World,” the Central Drugs Standard Control Organisation (CDSCO) has implemented several new rules:
- Mandatory Testing: Every batch of cough syrup intended for export or domestic sale must now undergo mandatory testing for DEG and Ethylene Glycol (EG) before being released to the market.
- QR Code Tracking: Phased rollout of QR codes on all pediatric medicine bottles to allow parents to verify the batch’s test results via a mobile app.
- Good Manufacturing Practices (GMP): All pharmaceutical units must now adhere to revised 2023-2025 GMP guidelines, which mandate stricter quality management systems.
5. What Parents Should Do
Health authorities are urging parents in India to shift their approach to common colds:
- Consult Experts: Never use leftover syrups or buy “cold and flu” medications for infants over the counter.
- Natural Alternatives: For children under 2, doctors recommend saline nasal drops, increased fluid intake, and honey (for children over 1 year) instead of chemical suppressants.
- Report Symptoms: If a child shows symptoms of vomiting, abdominal pain, or difficulty urinating after taking any medication, seek emergency medical care immediately.
“Most pediatric coughs are a natural defense mechanism and do not need a syrup,” stated a senior official from the Health Ministry. “We are prioritizing safety over the convenience of a quick-fix bottle.”
